Amphera

Executive Summary

Amphera is a late-stage clinical biotechnology company based in Maastricht, Netherlands, focused on developing MesoPher, an autologous dendritic cell therapy for cancer. Its lead indications are mesothelioma and pancreatic cancer, two challenging malignancies with high unmet medical need. MesoPher utilizes the patient's own dendritic cells loaded with PheraLys, a proprietary allogeneic tumor cell lysate that provides a broad spectrum of tumor antigens. The company aims to empower the immune system to recognize and attack cancer cells, leveraging the unique ability of dendritic cells to initiate and modulate immune responses. Amphera has advanced MesoPher into Phase 1 clinical trials, representing a promising approach in the burgeoning field of cell therapy for solid tumors. The company's innovative platform combines the specificity of dendritic cell vaccination with the breadth of antigen coverage from allogeneic lysates, potentially overcoming tumor heterogeneity and immune evasion. With a strong scientific foundation and focus on rare and orphan cancers, Amphera could address significant gaps in oncology. The path forward includes completing Phase 1 studies to establish safety and early efficacy signals, followed by dose optimization and potential expansion into larger trials. As a private company, Amphera may seek partnerships or additional financing to support its clinical development. With an experienced management team and a clear therapeutic rationale, the company represents a compelling opportunity in the immunotherapy space, though it remains early-stage with inherent clinical and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data for MesoPher in mesothelioma40% success
• Q1 2027Phase 1 interim data for MesoPher in pancreatic cancer35% success
• Q2 2027Strategic partnership or licensing deal for MesoPher20% success